NCT03729791

Brief Summary

The investigators conducted a randomized controlled trial to reveal the effect of tDCS on negative symptoms in patients with schizophrenia and its underlying mechanism using the neuroimaging and electrophysiology.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Dec 2019

Shorter than P25 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 30, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 5, 2018

Completed
1.1 years until next milestone

Study Start

First participant enrolled

December 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

1 year

First QC Date

October 30, 2018

Last Update Submit

April 21, 2026

Conditions

Keywords

SchizophreniatDCSnegative symptoms

Outcome Measures

Primary Outcomes (1)

  • Positive and Negative Syndrome Scale (PANSS)

    changes in psychopathology To assess a patient using PANSS, an approximately 45-minute clinical interview is conducted. The patient is rated from 1 to 7 on 30 different symptoms based on the interview as well as reports of family members or primary care hospital workers

    approximately 2 weeks (baseline and 2 weeks followups)

Secondary Outcomes (20)

  • The Clinical Assessment Interview for Negative Symptoms (CAINS)

    approximately 2 weeks (baseline and 2 weeks followups)

  • Electroencephalography - resting

    approximately 2 weeks (baseline and 2 weeks followups)

  • Electroencephalography - P300

    approximately 2 weeks (baseline and 2 weeks followups)

  • Electroencephalography - MMN

    approximately 2 weeks (baseline and 2 weeks followups)

  • Electroencephalography - ERN

    approximately 2 weeks (baseline and 2 weeks followups)

  • +15 more secondary outcomes

Study Arms (2)

actual tDCS

EXPERIMENTAL

2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions

Device: tDCS

sham tDCS

ACTIVE COMPARATOR

sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions

Device: tDCS

Interventions

tDCSDEVICE

Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way

actual tDCSsham tDCS

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • DSM-IV Schizophrenia
  • or more items of Negative symptom score in PANSS \> 5

You may not qualify if:

  • presences of neurological disorder or history
  • IQ \< 70
  • presence of severe personality disorders
  • presence of substance use disorder (except nicotin)
  • pregnancy
  • presence of severe medical condition or disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Schizophrenia

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Study Officials

  • Tae Young Lee, MD

    Seoul National University Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
All researchers will conduct research with only the encrypted subject number. A separate third-party researcher will participate to encrypt the subject and adjust the active/sham direction of the tDCS device during the actual research.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized controlled trial 1 arm is active tDCS and 1 arm is sham tDCS
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Professor

Study Record Dates

First Submitted

October 30, 2018

First Posted

November 5, 2018

Study Start

December 1, 2019

Primary Completion

December 1, 2020

Study Completion

December 1, 2020

Last Updated

April 24, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations